Invasion by hepatocellular carcinoma (HCC) has been reported to occur via the up-
regulation of nuclear factor-kappaB (NF-κB). Sorafenib can improve the overall survival in …

Abstract Sorafenib (Nexavar, BAY43‑9006 or Sora) is the first molecular targeted agent that
has exhibited significant therapeutic benefits in advanced hepatocellular carcinoma (HCC) …

The multi-kinase-inhibitor Sorafenib has been shown to prolong survival of patients suffering
from hepatocellular carcinoma (HCC). We investigated effects of the serine/threonine kinase …

Sorafenib is an oral multikinase inhibitor approved for the treatment of hepatocellular
carcinoma (HCC). Its antitumor activity is attributed to inhibition of tyrosine kinase receptors …

Sorafenib, the first‐line agent for treatment of advanced hepatocellular carcinoma (HCC),
improves median overall survival by approximately 3 months. In the present study, we …

Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely
causes tumor regression in patients with chronic liver diseases. To investigate whether …

Acquired resistance towards sorafenib treatment was found in HCC patients, which results in
poor prognosis. To investigate the enhanced metastatic potential of sorafenib resistance …

Background Treatment outcome of children with pediatric hepatocellular carcinoma (pHCC)
is poor. Therefore, we evaluated the tyrosine kinase inhibitor sorafenib in a model of pHCC …

Background/Aim: Sorafenib is currently the only medical treatment with proven efficacy
against hepatocellular carcinoma (HCC). HCC cell lines display heterogeneous sensitivity to …

Objectives Liver transplant can be a definitive treatment for hepatocellular carcinoma.
However, recurrence limits long-term survival. Sorafenib is the first agent to improve survival …